



ITOG 2021 Annual Meeting - Virtual

Wednesday, May 12 – Friday, May 14, 2021



INTERNATIONAL
THYROID ONCOLOGY
GROUP

THURSDAY, MAY 13, 2021

10:00AM - 4:30PM EST

SCIENTIFIC AGENDA

10:00 AM Doors Open

10:15 -10:30 AM Welcome and Announcements

Manisha Shah, ITOG President

10:30 - 11:00 AM Keynote Session 1

Moderator: Sareh Parangi

10:30 - 10:55 AM Functional profiling of immunotherapy response in organotypic tumor spheroids

David Barbie, MD

10:55 - 11:00 AM Discussion

11:00 - 12:30 PM SESSION I: Differentiated Thyroid Cancer (DTC)

Moderators: Bryan Haugen and Christine Spitzweg

11:00 - 11:20 AM Impact of Chromatin Remodelling in Thyroid Cancer Therapeutics

Jim Fagin, MD

11:20 - 11:40 AM TERT Promoter Mutation Provides a New Opportunity for Targeted Therapy of Thyroid Cancer

**Mingzhao Xing,
MD**

11:40 - 12:00 PM Altered cellular metabolism in thyroid cancer

**David McFadden,
MD PhD**

12:00 - 12:30 PM Discussion

12:30 - 01:00 PM Break and Networking

01:00 - 02:30 PM SESSION 2: Medullary Thyroid Cancer (MTC)

Moderators: Rosella Elisei and Lori Wirth

01:00 - 01:15 PM CAR-T Cells as Therapy for MTC

**Don Siegel, MD
PhD**

01:15 - 01:30 PM Acquired resistance to RET inhibitors

Jessica Lin, MD

01:30 - 01:45 PM Upregulating Somatostatin Receptors in MTC

**Herb Chen, MD,
FACS**

01:45 - 02:00 PM Role of CDK7/9 inhibitors in MTC and non-MTC

Matt Ringel, MD

02:00 - 02:30 PM Discussion



02:30 - 03:00 PM **Break and Networking**

03:00 - 04:00 PM **Business Meeting**

Manisha Shah, Sareh Parangi, Dwight Vicks

03:00 – 03:20 PM Celebrating Collaborative Teamwork at ITOG
Manisha Shah

03:20 – 03:30 PM No Money, No Mission at ITOG
Dwight Vicks

03:30 – 04:00 PM Discussion

04:00 - 04:25 PM **Gagel Awardee Talk**

Moderator: Yariv Houvras

04:00 - 04:15 PM Engineering a new mouse model of a thyroid-specific
lincRNA in BRAFV600E papillary thyroid carcinoma

**Carmelo Nucera,
MD PhD**

04:15 - 04:25 PM Discussion

04:25 - 04:30 PM **Thank You and Adjourn**

Sareh Parangi, MD ITOG Host Committee Chair



Friday, May 14, 2021
10:00 AM - 4:30PM EST
SCIENTIFIC AGENDA

- 10:00 -10:30 AM **Welcome and Vision**
Gregory Randolph, ITOG President Elect
- 10:30 - 11:00 AM **Keynote:**
Moderator: Sophie Leboulleux
- 10:30 - 10:55 AM An Odyssey in the Treatment of Metastatic Melanoma **Caroline Robert, MD PhD**
- 10:55 - 11:00 AM Discussion
- 11:00 - 01:00 PM **SESSION 3: Anaplastic Thyroid Cancer (ATC)**
Moderators: Keith Bible and Frank Worden
- 11:00 - 11:10AM Advances in management of ATC **Keith Bible MD PhD**
- 11:10 - 11:20AM Results of RTOG-0912 (Paclitaxel-Radiation) trial in ATC **Eric Sherman, MD**
- 11:20 - 11:30 AM Results of Spartalizumab Trial in ATC **Jaume Capdevila MD**
- 11:30 - 11:40 PM Results of Ipi/Nivo trial in ATC and future trials in ATC **Jochen Lorch, MD MSc**
- 11:40 - 11:50 AM **10 Minute Q & A**
- 11:50 - 12:05 PM Results of Targeted therapy + Atezo trial in ATC **Maria Cabanillas, MD**
- 12:05 - 12:20 PM Results of liquid biopsy in ATC patients **Laura Locati, MD**
Elisa Ortolan, PhD
- 12:20 - 12:35 PM Neoadjuvant D+T+Pembro retrospective data and upcoming trial **Mark Zafereo, MD**
- 12:35 - 12:45PM **10 Minute Q & A**



- 12:45 - 01:00 PM Discussion
- 01:00 - 01:30 PM **Break and Networking**
- 01:30 - 03:00 PM **SESSION 4: Clinical Trials**
(Closed session: Attendance restricted to non-industry ITOG members ONLY)
Moderators: Manisha Shah and Eric Sherman
- 01:30 - 01:45 PM Results of ACCRU-ITOG 1504 Len/Pembro in DTC: Cohorts 1 and 2 **Bryan Haugen, MD**
- 01:45 - 01:55 PM Final Results of Dabrafenib+/-Trametinib in BRAF-mutated DTC **Bhavana Konda, MD MPH**
- 01:55 - 02:05 PM **10 Mins Q&A**
- 02:05 - 02:15 PM Results of Combination therapy for Re-differentiation in BRAF and RAS mutated DTC **Sophie Leboulleux, MD**
- 02:15 - 02:25 PM Neo-adjuvant clinical trial in RET altered thyroid ca **Mark Zafereo, MD**
- 02:25 - 02:35 PM Re-differentiation trial for RAS mutant thyroid tumors **Alan Ho, MD PhD**
- 02:35 - 02:45 PM **10 Mins Q&A**
- 02:45 - 03:00 PM Discussion
- 03:00 - 03:30 PM **Break and Networking**
- 03:30 - 04:25 PM **SESSION 5: Brainstorming Session future ITOG studies**
(Closed session: Attendance restricted to non-industry ITOG members ONLY)
- 03:30 - 04:00 PM Re-differentiation Therapy/Trial Panel
Moderator: Alan Ho, MD
Panelists: James Fagin MD, Bryan Haugen MD, Sissy Jhiang PhD, Bhavana Konda, MD MPH, Sophie Leboulleux MD, Lori Wirth MD
- 04:00 - 04:25 PM Developing strategies for future ITOG Trials
Moderators: Manisha Shah and Greg Randolph
- 04:25 - 04:30 PM **Meeting Survey, Thank You and Adjourn**
Manisha Shah, ITOG President



ITOG MEMBER FACULTY

Keith Bible, MD PhD
Mayo Clinic

Maria Cabanillas, MD
MD Anderson Cancer Center

Jaume Capdevila Castillon, MD
Vall D'Hebron University Hospital,

Herb Chen, MD, FACS
University of Alabama-Birmingham

Rossella Elisei, MD
University of Pisa, Italy

James Fagin, MD
Memorial Sloan Kettering Cancer Center

Bryan Haugen, MD
University of Colorado Cancer Center

Alan Ho, MD, PhD
Memorial Sloan Kettering Cancer Center

Sissy Jhiang, PhD
Ohio State University

Bhavana Konda, MD MPH
Ohio State University

Sophie Leboulleux, MD
Gustave Roussy, France

Laura Locati, MD
Fondazione IRCCS Istituto Nazionale dei Tumori,
Italy

Jochen Lorch, MD MSc
Dana Farber Cancer Institute

David McFadden, MD PhD
University of Texas Southwestern Medical Center

Carmelo Nucera, MD PhD
Beth Israel Deaconess, Harvard Medical School

Matthew Ringel, MD
Ohio State University Medical Center

Eric Sherman, MD
Memorial Sloan Kettering Cancer Center

Julie Ann Sosa, MD
University of California - San Francisco

Mingzhao Xing, MD PhD
Southern University of Science and Technology

Mark Zafereo, MD
MD Anderson Cancer Center

GUEST FACULTY

David Barbie, MD
Dana Farber Cancer Institute

Jessica Lin, MD
Massachusetts General Hospital

Elisa Ortolan, PhD
Fondazione IRCCS Istituto Nazionale dei Tumori,
Italy

Caroline Robert, MD PhD
Gustave Roussy, France

Don Siegel, MD PhD
University of Pennsylvania Perelman School of
Medicine

ITOG MODERATORS

Keith Bible, MD PhD
Mayo Clinic

Rossella Elisei, MD
University of Pisa, Italy

Bryan Haugen, MD
University of Colorado Cancer Center

Yariv Houvras, MD
Weill Cornell Medical Center

Sophie Leboulleux, MD
Gustave Roussy, France

Gregory Randolph, MD
Massachusetts Eye and Ear

Sareh Parangi, MD
Harvard Medical School

Manisha Shah, MD
The Ohio State University

Christine Spitzweg, MD
University Hospital Munich, Ludwig-
Maximilians-University Munich

Lori Wirth, MD
Massachusetts General Hospital, Harvard

Frank Worden, MD
University of Michigan Health System



ITOG CLINICAL TRIALS

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

Accrual Status: Accruing at MDACC, Open to accrual Feb 2021.

Accrual Status: Accruing

Principal Investigator: Mark Zafereo, MD MD Anderson Cancer Center

Principle Investigator Email: Mzafereo@mdanderson.org

OSU 17277: A Phase 1 Trial of concurrent Intensity Modulated Radiation Therapy (IMRT) and Dabrafenib/Trametinb in BRAF Mutated Anaplastic or Poorly Differentiated Thyroid Cancer

Accrual Status: Accruing

Principal Investigator: Manisha Shah, MD The Ohio State University

Principle Investigator Email: Manisha.shah@osumc.edu

NCI 10240: Phase II Study of Cabozantinib in combination with Nivolumab and Ipilimumab (CaboNivoIpi) in Patients with Radioiodine-refractory Differentiated Thyroid Cancer whose Cancer Progressed after 1 Prior VEGFR-Targeted Therapy

Accrual Status: Accruing

City of Hope Comprehensive Cancer Center, Moffitt Cancer Center, University of Kentucky Cancer Center, University of Pittsburgh Cancer Institute, Mayo Clinic, Rochester, University of Southern California, Dana Farber, Memorial Sloan Kettering

Mayo Clinic-Florida, University of Utah, University of Kansas

Sponsors: CTEP/NCI, ITOG

Principal Investigator: Bhavana Konda, MD; The Ohio State University Coordinating organization: The Ohio State University

Principle Investigator Email: Bhavana.Konda@osumc.edu

ACCRU/ITOG 1504 Combination Immunotherapy with Multikinase Inhibitor (MKI) in Progressive, Radiodine-resistant Differentiated Thyroid Cancers

Accrual Status: Closed to Accrual

University of Michigan, University of Colorado, Dana-Farber/Harvard CC, Ohio State University, Memorial Sloan Kettering,

UCLA Medical Center, MD Anderson

Sponsors: Eisai/Merck Coordinating organization: ACCRU

Principal Investigator (PI): Bryan Haugen, MD at University of Colorado Medical Center

Principal Investigator Email: Bryan.Haugen@ucdenver.edu

Co-PI: Lori Wirth, MD

Publication/Presentation Status: ASCO 2020, ESMO 2020



Selumetinib plus RAI for RAI-Avid Thyroid Cancers

Accrual Status: Closed to Accrual

Sponsor: AstraZeneca Coordinating organization: ACCRU

Principal Investigator: Alan Ho, MD at Memorial Sloan-Kettering Cancer Center

Principal Investigator Email: hoa@mskcc.org

Co-PI: Mabel Ryder, MD

Publication/Presentation Status: Pending

Phase 1/2 Study of LOXO-292 in Patients with Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

Accrual Status: Accruing

Sponsor: Loxo-Oncology Coordinating organization: LOXO-Oncology

Leader at ITOG: Lori Wirth and ITOG protocol-specific steering committee

Leader Email: Lwirth@mgh.harvard.edu

Publication Status: Pending (N Engl J Med 2020, 383:825-835; August 27, 2020)

Presentations: ASCO Jun 2018, ATA Oct 2018

ALLIANCE A091302 Randomized Phase II Study of Sorafenib with or without Everolimus in Patients with Radioactive Iodine Refractory Hurthle Cell

Thyroid Cancer (PI- Dr. E. Sherman); Alliance study

Accrual Status: Permanently closed

Principal Investigator: Eric Sherman, MD Memorial-Sloan Kettering Cancer Center

Principal Investigator Email: shermane@mskcc.org

Publication: Pending

Presentation: ASCO 2021



Non-ITOG ATC Clinical Trials

Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

Sponsor: Stanford University

Principal Investigator: Saad A Khan, MD, Stanford University

NCT04552769

Atezolizumab With Chemotherapy in Treating Patients with Anaplastic or Poorly Differentiated Thyroid Cancer

Sponsor: M.D. Anderson Cancer Center

Principal Investigator: Maria E Cabanillas MD, Anderson Cancer Center

NCT03181100

Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

Sponsor: M.D. Anderson Cancer Center

Principal Investigator: Maria E Cabanillas M.D. Anderson Cancer Center

NCT04171622

LN-145 or LN-145-S1 in Treating Patients with Relapsed or Refractory Ovarian Cancer, Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Sponsor: M.D. Anderson Cancer Center

Principal Investigator: Amir A Jazaeri M.D. Anderson Cancer Center

NCT03449108

Pembrolizumab in Combination with Dabrafenib and Trametinib as a Neoadjuvant Strategy prior to Surgery in BRAF-mutated Anaplastic Thyroid Cancer

Sponsor: Merck; MD Anderson Cancer Center

Principal Investigator: Mark Zafereo, MD; Maria Cabanillas, MD

NCT04675710



ITOG MISSION STATEMENT

The mission of the International Thyroid Oncology Group is to catalyze a cure for the most challenging thyroid cancers through the collaborative efforts of our unique multidisciplinary team of leading physicians, scientists, and advocates to design, coordinate, and prioritize state-of-the-art clinical trials and correlative science.

Our members have led paradigm changing clinical trials for thyroid cancer patients. These trials have already resulted in the FDA approval of two new drugs for medullary thyroid cancer, and innovative new approaches for treating differentiated thyroid cancer. We are doctors, scientists, and patients whose lives and careers are focused on identifying new therapies for thyroid cancer.

This program is supported by an unrestricted educational grant from EXELIXIS and generous donations from ITOG Members and supporters.

(as of May 10, 2021)



ITOG Executive Committee

Manisha H. Shah, MD, President
The Ohio State University

Sareh Parangi, MD, Secretary
Massachusetts General Hospital

Eric Sherman, MD, Chair, Protocol Committee
Memorial Sloan Kettering Cancer Center

Dwight Vicks III, MBA CFO/Co-Founder
President, Vicks, Inc.

Greg Randolph, MD President Elect
Massachusetts Eye and Ear

ITOG Board of Directors

Naifa Busaidy, MD
MD Anderson Cancer Center

Andrew Gianoukakis, MD, Membership Chair
University of California, Los Angeles

Elizabeth Grubbs, MD
MD Anderson Cancer Center

Alan Ho MD, PhD, Correlative Sciences Chair
Memorial Sloan Kettering Cancer Center

Yariv Houvras, MD PHD
Weill Cornell Medical Center

Kate Newbold, MD
The Royal Marsden NHS

Sophie Leboulleux, MD International Liaison
Gustave Roussy

Mabel Ryder, MD
Mayo Clinic (Rochester)

Julie Ann Sosa, MD, Finance Committee Chair
University of California, San Francisco

Christine Spitzweg MD
University Hospital Munich, Ludwig-Maximilians-University Munich

Annual Meeting Planning Committee

Sareh Parangi MD, Chair
Harvard Medical School

Carmelo Nucera MD PhD, Co-Chair
Beth Israel Deaconess Medical Center
Harvard Medical School

Dwight Vicks III Co-Chair
Vicks Printing

Keith Bible MD PhD
Mayo Clinic

John Al Copland PhD
Mayo Clinic (Jacksonville)

Dora Dias-Santagata MD
Massachusetts General Hospital

Jochen Lorch MD MSc
Dana Farber Cancer Institute

Gregory Randolph MD
Massachusetts Eye and Ear

Matthew Ringel MD
Ohio State University

Mabel Ryder MD
Mayo Clinic (Rochester)

Wendy Sacks MD
Cedars Sinai Medical Center

Manisha Shah MD
Ohio State University

Eric Sherman MD
Memorial Sloan-Kettering

ITOG Staff

Judy Dallas
Administrator

Brenda Mitchell
Finance Manager

Video Production

Austin Talley
Virtual Producers



